Progressive Encephalomyelitis with Rigidity and Myoclonus with Glycine Receptor Antibodies (P4-2.001)

Mar Guasp; Albert Saiz; Marina Ruiz-Vives; Míriam Almendrote; Jordi Bruna; Jordi González-Menacho; Juntaro Kaneko; L. Aguilar; Francisco Antonio Martínez-García; Kazuyuki Noda; A Molina; Sara Sequeiros; Mateus Simabukuro; Megumi Takenaka; M. Zurdo; Josep Dalmau; Takahiro Iizuka; Francesc Graus

doi:10.1212/wnl.0000000000215784

Key Points

The research aims to elucidate the clinical characteristics and long-term prognosis of patients diagnosed with PERM associated with glycine receptor antibodies.
Descriptive analysis of clinical features in patients with glycine receptor antibodies.
Long-term outcome assessment of patients diagnosed with PERM.
Detailed presentation of clinical features observed in patients.
Assessment of long-term prognosis shows varying outcomes among affected individuals.

Implication

Describes clinical features and outcomes in patients with glycine receptor antibody-mediated PERM, highlighting its significance.

Abstract

The aim of this study was to describe the clinical features and long-term outcome of patients with glycine receptor (GlyR) antibody–mediated progressive encephalomyelitis with rigidity and myoclonus (PERM).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Guasp et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf403faef96ed7f0565a8 https://doi.org/10.1212/wnl.0000000000215784

View at Publisher

Ask AI

Bookmark

Share

Progressive Encephalomyelitis with Rigidity and Myoclonus with Glycine Receptor Antibodies (P4-2.001)

Key Points

Implication

Abstract

Discussion

Cite This Study

Progressive Encephalomyelitis with Rigidity and Myoclonus with Glycine Receptor Antibodies (P4-2.001)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Neurology

Keep reading

More related papers

More from Neurology